TARS - Goldman starts Tarsus at neutral says Xdemvy launch faces headwinds
2023-11-20 14:47:32 ET
More on Tarsus Pharmaceuticals
- Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript
- Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape
- Tarsus Pharmaceuticals, Inc. - Barking Up The Wrong Tree
- Tarsus Pharmaceuticals' President & CEO disposes 8,000 shares
- Seeking Alpha’s Quant Rating on Tarsus Pharmaceuticals
For further details see:
Goldman starts Tarsus at neutral, says Xdemvy launch faces headwinds